Tvardi Therapeutics TVRD
NASDAQ TVRD
$1.41 +0.00 (+0.30%)
As of: Nov 10, 2026 · 1:44 PM EST

Tvardi Therapeutics (TVRD) Cash from Restructuring (2024 - 2025)

Updated

Tvardi Therapeutics' Cash from Restructuring came in at -$352,000 for Q2 2025.

Analysis

Tvardi Therapeutics (TVRD) Cash from Restructuring (2024 - 2025) Analysis & Trends

For FY2024, Tvardi Therapeutics' Cash from Restructuring was $1.51 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn
10 Tvardi Therapeutics 12.48 Mn -95.62 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -352,000.00
Mar 31, 2025 781,000.00
Dec 31, 2024 439,000.00
API Access

Tvardi Therapeutics Cash from Restructuring API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-restructuring&ticker=TVRD&period=max&api_key=YOUR_API_KEY